Galectin Therapeutics Inc.
Galectin Therapeutics Inc. (GALT) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · GALT · as of Sep 30, 2025
Ownership Breakdown
90
Institutional Holders
▼ 2 vs Q2
$43.98M
Total Inst. Value
▲ $21.78M vs Q2
65.86M
Shares Outstanding
freeFloat 71.25%
10.34M
13F Shares Held
▼ 169,769 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
GALT largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC pharmaceutical preparations | 2.25M | 3.54% | 3.54% | $9.52B | Nov 7, 2025 | ▲ 63.4K |
ADVISOR GROUP HOLDINGS, INC. pharmaceutical preparations | 1.22M | 1.93% | 1.93% | $5.24B | Nov 14, 2025 | ▼ 40.7K |
BLACKROCK, INC. pharmaceutical preparations | 797.7K | 1.26% | 1.26% | $3.38B | Nov 12, 2025 | ▼ 94.2K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 633.1K | 99.78% | 99.78% | $2.68B | Nov 12, 2025 | ▼ 33.1K |
MARSHALL WACE, LLP pharmaceutical preparations | 554.3K | 87.36% | 87.36% | $2.35B | Nov 13, 2025 | ▲ 523.9K |
WEALTHSPIRE ADVISORS, LLC pharmaceutical preparations | 479.5K | 75.58% | 75.58% | $2.03B | Nov 14, 2025 | — held |
SUSQUEHANNA INTERNATIONAL GROUP, LLP pharmaceutical preparations | 446.6K | 70.39% | 70.39% | $1.89B | Nov 14, 2025 | ▲ 253.4K |
LPL FINANCIAL LLC pharmaceutical preparations | 360.3K | 56.78% | 56.78% | $1.53B | Nov 12, 2025 | ▼ 6.7K |
GENEOS WEALTH MANAGEMENT INC. pharmaceutical preparations | 360.2K | 56.77% | 56.77% | $1.53B | Oct 22, 2025 | ▼ 63.1K |
COMMONWEALTH EQUITY SERVICES, LLC pharmaceutical preparations | 294.9K | 46.48% | 46.48% | $1.25B | Oct 22, 2025 | ▲ 9.5K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
25
Increased
+1.38M shares1
New Positions
first time holders16
Decreased
−519.0K shares0
Sold Out
fully exitedNet shares change (top 50)
+865.4K
+1.38M / −519.0K
Net new holders
+10
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
GALT insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
1
Buy transactions
2
Sell transactions
0.50
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Jamil Khurram Chief Medical Officer | May 26, 2026 | Sale | 568 | $3.10 | $1.8K | 0 | Form 4 ↗ |
Brem Henry director | Mar 12, 2026 | Award | 60,000 | $3.16 | $189.6K | 60.0K | Form 4 ↗ |
ELDRED KARY director | Feb 6, 2026 | Purchase | 300 | $2.70 | $810 | 65.7K | Form 4 ↗ |
LEWIS JOEL President and CEO | Jan 16, 2026 | Award | 91,000 | $3.04 | $276.6K | 91.0K | Form 4 ↗ |
CARSON BENJAMIN SR director | Jan 16, 2026 | Award | 60,000 | $3.04 | $182.4K | 60.0K | Form 4 ↗ |
Zordani Richard A. Jr. director | Jan 16, 2026 | Award | 60,000 | $3.04 | $182.4K | 60.0K | Form 4 ↗ |
Jamil Khurram Chief Medical Officer | Jan 16, 2026 | Award | 65,000 | $3.04 | $197.6K | 65.0K | Form 4 ↗ |
FREEMAN KEVIN D director | Jan 16, 2026 | Award | 60,000 | $3.04 | $182.4K | 60.0K | Form 4 ↗ |
ELDRED KARY director | Jan 16, 2026 | Award | 60,000 | $3.04 | $182.4K | 60.0K | Form 4 ↗ |
LEWIS JOEL President and CEO | Jan 16, 2026 | Award | 84,000 | $3.04 | $255.4K | 65.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Galectin Therapeutics Inc. (GALT) is primarily owned by institutional investors, who hold approximately 15.7% of total shares outstanding. Company insiders own approximately 28.75%, while retail and public investors account for the remaining 55.55%.
The largest institutional shareholder of Galectin Therapeutics Inc. is VANGUARD GROUP INC, holding approximately 2.25 million shares — equal to 3.54% of outstanding shares — as of September 30, 2025.
A total of 90 institutional investors currently hold GALT stock, with a combined institutional value of approximately $43,976,380 as of the most recent 13F filing period.
Frequently asked questions
GALT ownershipGalectin Therapeutics Inc. (GALT) is primarily owned by institutional investors, who hold approximately 15.7% of shares. The largest shareholder is VANGUARD GROUP INC with a 3.54% stake. Company insiders hold 28.75%. Data sourced from SEC Form 13F as of September 30, 2025.